MxA as a Marker for Therapy Failure in HIV-Infected Children
Author Information
Author(s): Badolato Raffaele, Ghidini Claudia, Facchetti Fabio, Serana Federico, Sottini Alessandra, Chiarini Marco, Spinelli Elena, Lonardi Silvia, Plebani Alessandro, Caimi Luigi, Imberti Luisa
Primary Institution: Istituto di Medicina Molecolare 'Angelo Nocivelli', Department of Pediatrics, University of Brescia, Brescia, Italy
Hypothesis
The study aims to determine the role of interferon-alpha in controlling HIV infection in perinatally infected patients under antiretroviral therapy.
Conclusion
MxA mRNA levels may serve as a valuable marker to monitor the clinical response to therapy in HIV patients.
Supporting Evidence
- HIV replication unresponsive to antiretroviral treatment may lead to increased MxA mRNA expression.
- MxA mRNA levels correlated with HIV RNA copy numbers.
- Patients with low CD4+ counts showed severe depletion of plasmacytoid dendritic cells.
Takeaway
This study looked at how a specific gene, MxA, can help doctors understand if HIV treatment is working for kids who got the virus at birth.
Methodology
The study used flow cytometry, real-time PCR, and ELISA to analyze plasmacytoid dendritic cells and measure interferon-alpha and MxA mRNA levels.
Limitations
The study did not assess pDC counts before treatment and relied on a small sample size.
Participant Demographics
33 perinatally HIV-infected patients aged 2 to 19 years, with a mix of male and female participants.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website